Division of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Division of Biological Science, Excellence Research Laboratory on Natural Products, Faculty of Science and Natural Product Research Center of Excellence, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
PLoS One. 2021 Jan 6;16(1):e0244673. doi: 10.1371/journal.pone.0244673. eCollection 2021.
Multidrug resistant Enterobacterales have become a serious global health problem, with extended hospital stay and increased mortality. Antibiotic monotherapy has been reported ineffective against most drug resistant bacteria including Klebsiella pneumoniae, thus encouraging the use of multidrug therapies as an alternative antibacterial strategy. The present works assessed the antibacterial activity of colistin against K. pneumoniae isolates. Resistant isolates were tested against 16 conventional antibiotics alone and in combination with colistin. The results revealed that all colistin resistant isolates demonstrated multidrug resistance against the tested antibiotics except amikacin. At sub-inhibitory concentrations, combinations of colistin with amikacin, or fosfomycin showed synergism against 72.72% (8 of 11 isolates). Colistin with either of gentamicin, meropenem, cefoperazone, cefotaxime, ceftazidime, moxifloxacin, minocycline, or piperacillin exhibited synergism against 81.82% (9 of 11 isolates). Combinations of colistin with either of tobramycin or ciprofloxacin showed synergism against 45.45% (5 in 11 isolates), while combinations of colistin with imipenem or ceftolozane and tazobactam displayed 36.36% (4 of 11 isolates) and 63.64% (7 of 11 isolates) synergism. In addition, combinations of colistin with levofloxacin was synergistic against 90.91% (10 of 11 isolates). The results revealed that combinations of colistin with other antibiotics could effectively inhibit colistin resistant isolates of K. pneumoniae, and thus could be further explore for the treatment of multidrug resistant pathogens.
多药耐药肠杆菌科已成为一个严重的全球健康问题,导致住院时间延长和死亡率增加。据报道,抗生素单药治疗对大多数耐药菌(包括肺炎克雷伯菌)无效,因此鼓励使用多药治疗作为替代抗菌策略。本研究评估了黏菌素对肺炎克雷伯菌分离株的抗菌活性。耐药分离株单独和与黏菌素联合测试了 16 种常规抗生素。结果表明,所有黏菌素耐药分离株对测试的抗生素均表现出多药耐药性,除阿米卡星外。在亚抑菌浓度下,黏菌素与阿米卡星或磷霉素联合对 72.72%(11 株中的 8 株)表现出协同作用。黏菌素与庆大霉素、美罗培南、头孢哌酮、头孢噻肟、头孢他啶、莫西沙星、米诺环素或哌拉西林中的任何一种联合使用对 81.82%(11 株中的 9 株)表现出协同作用。黏菌素与妥布霉素或环丙沙星中的任何一种联合使用对 45.45%(11 株中的 5 株)表现出协同作用,而黏菌素与亚胺培南或头孢他唑巴坦联合使用对 36.36%(11 株中的 4 株)和 63.64%(11 株中的 7 株)表现出协同作用。此外,黏菌素与左氧氟沙星联合使用对 90.91%(11 株中的 10 株)表现出协同作用。结果表明,黏菌素与其他抗生素联合使用可以有效抑制黏菌素耐药的肺炎克雷伯菌分离株,因此可以进一步探索用于治疗多药耐药病原体。